Kerr on Oncology
David J. Kerr, MD, is a professor of cancer medicine at the University of Oxford in Oxford, England. He is recognized internationally for his work in the research and treatment of colorectal cancer, and has published more than 400 papers. He has founded three university spin-out companies: COBRA Therapeutics, Celleron Therapeutics, and Oxford Cancer Biomarkers. In 2002, he was appointed Commander of the British Empire by Queen Elizabeth and in 2010 was elected president of the European Society for Medical Oncology.+ Add to Email Alerts
- The Mental Impact of Multicancer Early-Detection Testing
- COLLISION: Thermal Ablation in Colorectal Liver Metastases
- Addressing Overtreatment in End-of-Life Cancer Care
- Benefits of Playing Drums: Physical, Mental, and Social
- UK’s Assisted Dying Legislation: Balancing Pros and Cons
- Patients Have the Right to Try Experimental Cancer Therapies
- Have Your Cake and Eat It, Too: 'The Great British Bake Off'
- Could Diet and Gut Bacteria Be Fueling Early CRC?
- How Doctor Who May Have Helped UK Health Over the Holidays
- Treating Patients You Dislike: Is It Possible?
- Are Targeted Drugs the Future in Colorectal Cancer?
- Should There Be a Mandatory Retirement Age for Physicians?
- Improving Cancer Treatment Selection for At-Risk Patients
- Cancer-Related Medical Debt Necessitates 'Safety Net'
- Colorectal Cancer On the Rise in Young Adults
- Aspirin Use Enhances Immunosurveillance in Colorectal Cancer
- Treating Patients With Cancer From Prison: A Complex Reality
- 'We're Just Not Doing It Right': Caring for Medical Students
- Guidelines Don’t Eliminate Variations in Chemotherapy Uptake
- Mapping a Positive Way Forward for Bowel Cancer Screening